Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

A group of faith leaders, community advocates, and activists continues to call on the Monroe County District Attorney's ...

Filmmaker Patricia Riggen believes a remake of her 2007 film would be far too grim in today's political landscape.

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

The U.S. Court of Appeals for the 5th Circuit is considering whether the president properly invoked the Alien Enemies Act to ...

The survey also comes as tensions heat up between Israel and Iran and concerns Israel could launch a strike on Tehran's nuclear plants.

Meet Emanuel Colombini of Eccentrica Cars, whose Lamborghini Diablo restomod is an analogue supercar for the modern age ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...